Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664801 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT06664801 is a Phase 2 study of Pulmonary Arterial Hypertension that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 164 participants, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06664801, a Phase 2 study of Pulmonary Arterial Hypertension, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it
Conditions Studied
Interventions
- BIOLOGICAL Sotatercept
- BIOLOGICAL Background PAH Therapy
Study Locations (20)
Other
- Hospital Britanico de Buenos Aires ( Site 0004) - CABA
- Instituto de Cardiologia Juana F. Cabral ( Site 0008) - Corrientes
- Hospital Provincial Jose Maria Cullen ( Site 0005) - Santa Fe
Buenos Aires
- Centro Medico Capital ( Site 0002) - La Plata
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006) - Mar del Plata
New South Wales
- Royal Prince Alfred Hospital ( Site 0103) - Camperdown
- Westmead Hospital ( Site 0100) - Westmead
Arizona
- Pulmonary Associates, PA ( Site 1903) - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930) - Aurora
Indiana
- Indiana University Health Methodist Hospital ( Site 1905) - Indianapolis
Kansas
- University of Kansas Medical Center ( Site 1928) - Kansas City
Kentucky
- Norton Pulmonary Specialists ( Site 1935) - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06664801
The ClinicalTrials.gov registry entry for NCT06664801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (64% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Sotatercept is the first listed.
NCT06664801 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Buenos Aires, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06664801 about?
NCT06664801 is a clinical study titled "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)". Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time wh...
What is the current status of trial NCT06664801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2024-11-14. Estimated completion is 2025-11-20.
What conditions does trial NCT06664801 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06664801?
The interventions under investigation include: Sotatercept (BIOLOGICAL), Background PAH Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT06664801?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664801 being conducted?
This trial has 20 study locations across Arizona, Colorado, Indiana, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.